Live search
TopFind is fetching the latest matches for your search.
We reviewed 6 live results for bat2206 ustekinumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Immunology and Pharmaceuticals.
Source: Dr. Reddy’s Laboratories
Description
BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis.
Best for
Plaque psoriasis, Psoriatic arthritis and Autoimmune disease treatment
Rating
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
Patients in South Korea, Psoriasis treatment and Local biosimilar seekers
Rating
Source: Janssen
Description
Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion.
Best for
Pediatric psoriasis patients, Singapore Based healthcare users, Established biologic treatment and Ulcerative colitis management
Rating
| Compare | BAT2206 (Ustekinumab) | Epyztek (ustekinumab) | Stelara (ustekinumab) |
|---|---|---|---|
| Source | Dr. Reddy’s Laboratories | Samsung Bioepis | Janssen |
| Description | BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis. | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. | Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion. |
| Best for | Plaque psoriasis, Psoriatic arthritis and Autoimmune disease treatment | Patients in South Korea, Psoriasis treatment and Local biosimilar seekers | Pediatric psoriasis patients, Singapore Based healthcare users, Established biologic treatment and Ulcerative colitis management |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"BAT2206 (Ustekinumab) from Dr. Reddy’s Laboratories."
I picked this because This biosimilar represents the latest advancements in autoimmune treatments coming to the Philippine market in 2025.